Patents by Inventor Daniel Mullen

Daniel Mullen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Peptides for altering bone resorption, angiogenesis and restenosis
    Patent number: 5849865
    Abstract: The present invention provides Arg-Gly-Asp peptides that can alter the binding of osteoclasts to a matrix such as bone or can selectively alter integrin receptor binding. The invention also provides methods of using the Arg-Gly-Asp peptides to alter .alpha..sub.v .beta..sub.3 integrin receptor-mediated binding of a cell such as an osteoclast, endothelial cell or smooth muscle cell to a matrix. The invention further provides methods for ameliorating the severity of a pathology characterized, in part, by an undesirable level of bone resorption, angiogenesis or restenosis in a subject.
    Type: Grant
    Filed: April 12, 1995
    Date of Patent: December 15, 1998
    Assignee: La Jolla Cancer Research Foundation
    Inventors: Soan Cheng, Ronald Ingram, Daniel Mullen, Juerg F. Tschopp
  • Peptides useful for altering bone resorption
    Patent number: 5807819
    Abstract: The present invention provides Arg--Gly--Asp peptides that can alter the binding of osteoclasts to a matrix such as bone or can selectively alter integrin receptor binding. The invention also provides methods of using the Arg--Gly--Asp peptides to alter .alpha..sub.V .beta..sub.3 integrin receptor-mediated binding of a cell such as an osteoclast, endothelial cell or smooth muscle cell to a matrix. The invention further provides methods for ameliorating the severity of a pathology characterized, in part, by an undesirable level of bone resorption, angiogenesis or restenosis in a subject.
    Type: Grant
    Filed: April 12, 1995
    Date of Patent: September 15, 1998
    Assignee: La Jolla Cancer Research Center
    Inventors: Soan Cheng, Ronald Ingram, Daniel Mullen, Juerg F. Tschopp
  • Use of peptides for altering bone resorption
    Patent number: 5792745
    Abstract: The present invention provides Arg-Gly-Asp peptides that can alter the binding of osteoclasts to a matrix such as bone or can selectively alter integrin receptor binding. The invention also provides methods of using the Arg-Gly-Asp peptides to alter .alpha..sub.v .beta..sub.3 integrin receptor-mediated binding of a cell such as an osteoclast, endothelial cell or smooth muscle cell to a matrix. The invention further provides methods for ameliorating the severity of a pathology characterized, in part, by an undesirable level of bone resorption, angiogenesis or restenosis in a subject.
    Type: Grant
    Filed: April 12, 1995
    Date of Patent: August 11, 1998
    Assignee: La Jolla Cancer Research Center
    Inventors: Soan Cheng, Ronald Ingram, Daniel Mullen, Juerg F. Tschopp
  • Use of peptides for altering .alpha..sub.V .beta..sub.3 -mediated binding
    Patent number: 5773412
    Abstract: The present invention provides Arg--Gly--Asp peptides that can alter the binding of osteoclasts to a matrix such as bone or can selectively alter integrin receptor binding. The invention also provides methods of using the Arg--Gly--Asp peptides to alter .alpha..sub.v .beta..sub.3 integrin receptor-mediated binding of a cell such as an osteoclast, endothelial cell or smooth muscle cell to a matrix. The invention further provides methods for ameliorating the severity of a pathology characterized, in part, by an undesirable level of bone resorption, angiogenesis or restenosis in a subject.
    Type: Grant
    Filed: April 12, 1995
    Date of Patent: June 30, 1998
    Assignee: La Jolla Cancer Research Center
    Inventors: Soan Cheng, Ronald Ingram, Daniel Mullen, Juerg F. Tschopp
  • Peptides for reducing or inhibiting bone resorption
    Patent number: 5770565
    Abstract: The present invention provides Arg-Gly-Asp peptides that can reduce or inhibit the binding of osteoclasts to a matrix such as bone or can selectively alter integrin receptor binding. The invention also provides methods of using the Arg-Gly-Asp peptides to reduce or inhibit osteoclast binding to a matrix, to reduce or inhibit bone resorption in a subject and to alter .alpha..sub.V .beta..sub.3 binding.
    Type: Grant
    Filed: September 8, 1994
    Date of Patent: June 23, 1998
    Assignee: La Jolla Cancer Research Center
    Inventors: Soan Cheng, Ronald Ingram, Daniel Mullen, Juerg Tschopp
  • Peptides useful for altering .alpha..sub.v .beta..sub.3 -mediated binding
    Patent number: 5759996
    Abstract: The present invention provides Arg-Gly-Asp peptides that can alter the binding of osteoclasts to a matrix such as bone or can selectively alter integrin receptor binding. The invention also provides methods of using the Arg-Gly-Asp peptides to alter .alpha..sub.v .beta..sub.3 integrin receptor-mediated binding of a cell such as an osteoclast, endothelial cell or smooth muscle cell to a matrix. The invention further provides methods for ameliorating the severity of a pathology characterized, in part, by an undesirable level of bone resorption, angiogenesis or restenosis in a subject.
    Type: Grant
    Filed: April 12, 1995
    Date of Patent: June 2, 1998
    Assignee: La Jolla Cancer Research Center
    Inventors: Soan Cheng, Ronald Ingram, Daniel Mullen, Juerg F. Tschopp